| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
The primary target of DCG066 is the lysine methyltransferase G9a (also known as EHMT2). It acts as a direct inhibitor of G9a, binding to the enzyme and inhibiting its methyltransferase activity. By inhibiting G9a, it reduces H3K9Me2 levels, leading to altered gene expression. This mechanism underlies its anticancer activity.
|
|---|---|
| ln Vitro |
DCG066 directly binds to G9a and inhibits its methyltransferase activity in vitro. It decreases H3K9Me2 levels, inhibits cell proliferation, and induces apoptosis. It displays low cytotoxicity in leukemia cell lines with high G9a expression, including K562. Detailed IC50 values are not consistently reported.
|
| ln Vivo |
In vivo data for DCG066 are limited. The compound is primarily characterized in in vitro systems. Its inhibition of G9a and antiproliferative activity against leukemia cells warrant further in vivo investigation. Detailed pharmacokinetic and efficacy data in animal models are not extensively documented.
|
| Enzyme Assay |
For non-cellular enzyme inhibition assays, recombinant G9a is incubated with DCG066 in the presence of SAM and a peptide substrate. Methyl transfer is quantified by scintillation counting. Binding is assessed by surface plasmon resonance or isothermal titration calorimetry.
|
| Cell Assay |
In vitro cell experiments employ leukemia cell lines such as K562. DCG066 is added, and cell proliferation is measured by MTT assays. H3K9Me2 levels are assessed by Western blotting. Apoptosis is evaluated by flow cytometry or caspase activity assays.
|
| Animal Protocol |
Animal studies for DCG066 are limited. The compound is primarily characterized in in vitro systems. Detailed pharmacokinetic and efficacy data in animal models are not extensively documented. All products are for research use only.
|
| References |
| Molecular Formula |
C30H31F6N3O2
|
|---|---|
| Molecular Weight |
579.58
|
| Exact Mass |
579.23
|
| Elemental Analysis |
C, 62.17; H, 5.39; F, 19.67; N, 7.25; O, 5.52
|
| CAS # |
494786-13-9
|
| PubChem CID |
11837558
|
| Appearance |
Solid powder
|
| LogP |
5.8
|
| tPSA |
55.8
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
41
|
| Complexity |
800
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC(C1C=CC(=CC=1)C(C1C=CC(C(F)(F)F)=CC=1)(C1CCN(CC2C=CC(=CC=2)NC(N(C)C)=O)CC1)O)(F)F
|
| InChi Key |
PMPKMTDYPOAEEH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C30H31F6N3O2/c1-38(2)27(40)37-26-13-3-20(4-14-26)19-39-17-15-23(16-18-39)28(41,21-5-9-24(10-6-21)29(31,32)33)22-7-11-25(12-8-22)30(34,35)36/h3-14,23,41H,15-19H2,1-2H3,(H,37,40)
|
| Chemical Name |
3-[4-[[4-[hydroxy-bis[4-(trifluoromethyl)phenyl]methyl]piperidin-1-yl]methyl]phenyl]-1,1-dimethylurea
|
| Synonyms |
DCG066; DCG-066; DCG 066;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~172.5 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (8.63 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7254 mL | 8.6269 mL | 17.2539 mL | |
| 5 mM | 0.3451 mL | 1.7254 mL | 3.4508 mL | |
| 10 mM | 0.1725 mL | 0.8627 mL | 1.7254 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.